Journal
VIRUSES-BASEL
Volume 14, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/v14071507
Keywords
SARS-CoV-2; COVID-19; cell model; animal model; drug
Categories
Ask authors/readers for more resources
This article reviews the information on available SARS-CoV-2 preclinical models and discusses their development, advantages, drawbacks, and relevance to drug effectiveness evaluation.
During the last two years following the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, development of potent antiviral drugs and vaccines has been a global health priority. In this context, the understanding of virus pathophysiology, the identification of associated therapeutic targets, and the screening of potential effective compounds have been indispensable advancements. It was therefore of primary importance to develop experimental models that recapitulate the aspects of the human disease in the best way possible. This article reviews the information concerning available SARS-CoV-2 preclinical models during that time, including cell-based approaches and animal models. We discuss their evolution, their advantages, and drawbacks, as well as their relevance to drug effectiveness evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available